Tolerability and Pharmacokinetics Following a Single Dose of Vardenafil in Healthy Korean Volunteers
![]() ![]() |
Kim, Seokuee
(Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Lee, SeungHwan (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Lim, Kyoung Soo (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Lim, Hyeong-Seok (Department of Clinical Pharmacology and Therapeutics, University of Ulsan and Asan Medical Center) Shin, Sang-Goo (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Jang, In-Jin (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) |
1 | Park SY, Kang YS, Jeong MS, Yoon HK, Han KO. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther, 2008;33(1):61-65. DOI ScienceOn |
2 | Choi MK, Song IS. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. J Pharm Pharmacol, 2012;64(8): 1074-1083. DOI ScienceOn |
3 | Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med, 2004;1(1):6-23. DOI ScienceOn |
4 | Albersen M, Orabi H, Lue TF. Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. Gerontology, 2012;58(1): 3-14. DOI ScienceOn |
5 | Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol, 2010;57(5):804-814. DOI ScienceOn |
6 | Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med, 2007;120(2):151-157. DOI ScienceOn |
7 | Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA, 2005;294(23): 2996-3002. DOI ScienceOn |
8 | Cho BL, Kim YS, Choi YS, Hong MH, Seo HG, Lee SY, Shin HC, Kim CH, Moon YS, Cha HS, Kim BS. Prevalence and risk factors for erectile dysfunction in primary care: results of a Korean study. Int J Impot Res, 2003;15(5): 323-328. DOI ScienceOn |
9 | Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol, 1994;151(1):54-61. |
10 | Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol, 2005; 45(9):987-1003. DOI ScienceOn |
11 | Research CfDEa. NDA 021400 Levitra (Vardenafil Hydrochloride) Tablets: Clinical Pharmacology / Biopharmaceutics Review. Rockville, Md: Department of Health and Human Services, US Food and Drug Administration, 2003. |
12 | EMEA. Scientific discussion for the approval of Levitra [Online] (last visited on 27 May 2012). |
13 | Shon JH, Ku HY, Bae SY, Oh MK, Yeo CW, Bae SK, Shin JG. The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genom, 2011;21(12):820-828. DOI ScienceOn |
14 | Dorne JL, Walton K, Renwick AG. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol, 2003;41(2): 201-224. DOI ScienceOn |
![]() |